NCT06723626 Effects of Intravenous Metabolic Recovery Agent in Elderly Septic Patients on Prognosis and Microcirculation.
| NCT ID | NCT06723626 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Southeast University, China |
| Condition | Septic Shock |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2025-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-07-01 with a primary completion date of 2025-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study intends to observe the effect of intravenous hydrocortisone combined with vitamin C and vitamin B1 infusion on the prognosis and sublingual microcirculation in patients with sepsis or septic shock through a prospective randomized controlled study method.
Eligibility Criteria
Inclusion Criteria: * Age ≥60 and ≤85 years old; * Diagnosis of sepsis or septic shock; * Clinical judgment for hydrocortisone treatment; * Signing Informed Consent. Exclusion Criteria: * patients in palliative care; * uncontrolled malignancy with multiple metastases; * ineffective surgical intervention for the infectious agent; * estimated death within 24 hours; * glucocorticoids used in the last 7 days; * allergy to hydrocortisone, vitamin c or vitamin B1; * inability to measure sublingual microcirculation.
Contact & Investigator
Jingyuan Xu, M.D.
PRINCIPAL INVESTIGATOR
Zhongda Hospital
Frequently Asked Questions
Who can join the NCT06723626 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 85 Years, studying Septic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06723626 currently recruiting?
Yes, NCT06723626 is actively recruiting participants. Contact the research team at xujingyuanmail@163.com for enrollment information.
Where is the NCT06723626 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06723626 clinical trial?
NCT06723626 is sponsored by Southeast University, China. The principal investigator is Jingyuan Xu, M.D. at Zhongda Hospital. The trial plans to enroll 40 participants.